Buprenorphine-naloxone treatment in opioid dependence and risk of liver enzyme elevation: Results from a 12-month observational study

American Journal on Addictions

Volumn 23, Issue 6, 2014, Pages 563-569

  Soyka, Michael ^a,b   Backmund, Markus ^c   Schmidt, Peggy ^a,b   Apelt, Sabine ^a,d  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Private Hospital Meiringen   (Switzerland)

^c PiT Praxis im Tal   (Germany)

^d Certum Consulting Scientific Research   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BUPRENORPHINE PLUS NALOXONE; ALKALINE PHOSPHATASE; BUPRENORPHINE; GAMMA GLUTAMYLTRANSFERASE; NALOXONE; NARCOTIC ANTAGONIST;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; DRUG SAFETY; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; HYPERTRANSAMINASEMIA; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OPIATE ADDICTION; OUTCOME ASSESSMENT; PHASE 4 CLINICAL TRIAL; PROSPECTIVE STUDY; SEX DIFFERENCE; TOXIC HEPATITIS; UNSPECIFIED SIDE EFFECT; ADVERSE EFFECTS; BLOOD; COHORT ANALYSIS; DRUG-INDUCED LIVER INJURY; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS;

ADULT; ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASES; BUPRENORPHINE; COHORT STUDIES; DRUG-INDUCED LIVER INJURY; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; MALE; NALOXONE; NARCOTIC ANTAGONISTS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PROSPECTIVE STUDIES;

EID: 84922331007     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1111/j.1521-0391.2014.12131.x     Document Type: Article

References (36)

1. Kakko J, Svanborg KD, Kreek MJ, et al. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet. 2003; 361: 662-668.
2. Kleber HD, Weiss RD, Anton RF Jr, et al. Treatment of patients with substance use disorders, second edition. American Psychiatric Association. Am J Psychiatry. 2007; 164: 5-123.
3. Mammen K, Bell J., The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence. Expert Opin Pharmacother. 2009; 10: 2537-2544.
4. Orman JS, Keating GM., Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence. Drugs. 2009; 69: 577-607.
5. Schottenfeld RS, Pakes JR, Oliveto A, et al. Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch Gen Psychiatry. 1997; 54: 713-720.
6. Soyka M, Kranzler HR, van den Brink W, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of substance use and related disorders. Part 2: opioid dependence. World J Biol Psychiatry. 2011; 12: 160-187.
7. Soyka M, Trader A, Klotsche J, et al. Six-year mortality rates of patients in methadone and buprenorphine maintenance therapy: results from a nationally representative cohort study. J Clin Psychopharmacol. 2011; 31: 678-680.
8. Soyka M, Zingg C, Koller G, et al. Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: results from a randomized study. Int J Neuropsychopharmacol. 2008; 11: 641-653.
9. Novick DM, Kreek MJ, Fanizza AM, et al. Methadone disposition in patients with chronic liver disease. Clin Pharmacol Ther. 1981; 30: 353-362.
10. Abraham HD, Degli-Esposti S, Marino L., Seroprevalence of hepatitis C in a sample of middle class substance abusers. J Addict Dis. 1999; 18: 77-87.
11. Diaz T, Des Jarlais DC, Vlahov D, et al. Factors associated with prevalent hepatitis C: differences among young adult injection drug users in lower and upper Manhattan, New York City. Am J Public Health. 2001; 91: 23-30.
12. Murrill CS, Weeks H, Castrucci BC, et al. Age-specific seroprevalence of HIV, hepatitis B virus, and hepatitis C virus infection among injection drug users admitted to drug treatment in 6 US cities. Am J Public Health. 2002; 92: 385-387.
13. Novick DM, Kreek MJ., Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients. Addiction. 2008; 103: 905-918.
14. Patrick DM, Tyndall MW, Cornelisse PG, et al. Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection. CMAJ. 2001; 165: 889-895.
15. Rosenblum A, Nuttbrock L, McQuistion HL, et al. Hepatitis C and substance use in a sample of homeless people in New York City. J Addict Dis. 2001; 20: 15-25.
16. Backmund M, Schutz CG, Meyer K, et al. Alcohol consumption in heroin users, methadone-substituted and codeine-substituted patients-Frequency and correlates of use. Eur Addict Res. 2003; 9: 45-50.
17. Aithal GP, Watkins PB, Andrade RJ, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011; 89: 806-815.
18. Abboud G, Kaplowitz N., Drug-induced liver injury. Drug Saf. 2007; 30: 277-294.
19. Lee WM, Senior JR., Recognizing drug-induced liver injury: current problems, possible solutions. Toxicol Pathol. 2005; 33: 155-164.
20. Berson A, Fau D, Fornacciari R, et al. Mechanisms for experimental buprenorphine hepatotoxicity: major role of mitochondrial dysfunction versus metabolic activation. J Hepatol. 2001; 34: 261-269.
21. Berson A, Gervais A, Cazals D, et al. Hepatitis after intravenous buprenorphine misuse in heroin addicts. J Hepatol. 2001; 34: 346-350.
22. Bruce RD, Altice FL., Case series on the safe use of buprenorphine/naloxone in individuals with acute hepatitis C infection and abnormal hepatic liver transaminases. Am J Drug Alcohol Abuse. 2007; 33: 869-874.
23. Zuin M, Giorgini A, Selmi C, et al. Acute liver and renal failure during treatment with buprenorphine at therapeutic dose. Dig Liver Dis. 2009; 41: e8-e10.
24. Apelt SM, Scherbaum N, Golz J, et al. Safety, effectiveness and tolerance of buprenorphine-naloxone in the treatment of opioid dependence: results from a nationwide non-interventional study in routine care. Pharmacopsychiatry. 2013; 46: 94-107.
25. Saxon AJ, Ling W, Hillhouse M, et al. Buprenorphine/naloxone and methadone effects on laboratory indices of liver health: a randomized trial. Drug Alcohol Depend. 2013; 128: 71-76.
26. Petry NM, Bickel WK, Piasecki D, et al. Elevated liver enzyme levels in opioid-dependent patients with hepatitis treated with buprenorphine. Am J Addict. 2000; 9: 265-269.
27. Houdret N, Asnar V, Szostak-Talbodec N, et al. Hepatonephritis and massive ingestion of buprenorphine. Acta Clin Belg Suppl. 1999; 1: 29-31.
28. Peyriere H, Tatem L, Bories C, et al. Hepatitis after intravenous injection of sublingual buprenorphine in acute hepatitis C carriers: report of two cases of disappearance of viral replication after acute hepatitis. Ann Pharmacother. 2009; 43: 973-977.
29. Herve S, Riachi G, Noblet C, et al. Acute hepatitis due to buprenorphine administration. Eur J Gastroenterol Hepatol. 2004; 16: 1033-1037.
30. McNicholas LF, Holbrook AM, O'Grady KE, et al. Effect of hepatitis C virus status on liver enzymes in opioid-dependent pregnant women maintained on opioid-agonist medication. Addiction. 2012; 107 (Suppl 1): 91-97.
31. Bogenschutz MP, Abbott PJ, Kushner R, et al. Effects of buprenorphine and hepatitis C on liver enzymes in adolescents and young adults. J Addict Med. 2010; 4: 211-216.
32. Vergara-Rodriguez P, Tozzi MJ, Botsko M, et al. Hepatic safety and lack of antiretroviral interactions with buprenorphine/naloxone in HIV-infected opioid-dependent patients. J Acquir Immune Defic Syndr. 2011; 56: S62-S67.
33. Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010; 363: 2320-2331.
34. Elkader A, Sproule B., Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin Pharmacokinet. 2005; 44: 661-680.
35. George J, Murray M, Byth K, et al. Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease. Hepatology. 1995; 21: 120-128.
36. Yang LQ, Li SJ, Cao YF, et al. Different alterations of cytochrome P450 3A4 isoform and its gene expression in livers of patients with chronic liver diseases. World J Gastroenterol. 2003; 9: 359-363.